These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23821159)

  • 21. Exploring the Potential Routine Use of Electronic Healthcare Record Data to Strengthen Early Signal Assessment in UK Medicines Regulation: Proof-of-Concept Study.
    Donegan K; Owen R; Bird H; Burch B; Smith A; Tregunno P
    Drug Saf; 2018 Sep; 41(9):899-910. PubMed ID: 29725942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application and optimisation of the Comparison on Extreme Laboratory Tests (CERT) algorithm for detection of adverse drug reactions: Transferability across national boundaries.
    Tham MY; Ye Q; Ang PS; Fan LY; Yoon D; Park RW; Ling ZJ; Yip JW; Tai BC; Evans SJ; Sung C
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):87-94. PubMed ID: 29108136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implementing a centralised pharmacovigilance service in a non-commercial setting in the United Kingdom.
    Dinnett EM; Kean S; Tolmie EP; Ronald ES; Gaw A
    Trials; 2013 Jun; 14():171. PubMed ID: 23758677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety signal detection: the relevance of literature review.
    Pontes H; Clément M; Rollason V
    Drug Saf; 2014 Jul; 37(7):471-9. PubMed ID: 24895178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase
    Vogel U; van Stekelenborg J; Dreyfus B; Garg A; Habib M; Hosain R; Wisniewski A
    Drug Saf; 2020 Apr; 43(4):351-362. PubMed ID: 32020559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A description of medicines-related safety issues evaluated through a referral procedure at the EU level after 2012.
    Farcas A; Balcescu T; Anghel L; Bucsa C; Mogoșan C
    Expert Opin Drug Saf; 2020 Jun; 19(6):755-762. PubMed ID: 32186202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacovigilance in developing countries (part I): importance and challenges.
    Elshafie S; Zaghloul I; Roberti AM
    Int J Clin Pharm; 2018 Aug; 40(4):758-763. PubMed ID: 29248988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacovigilance of herbal medicines : a UK perspective.
    Barnes J
    Drug Saf; 2003; 26(12):829-51. PubMed ID: 12959628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of safety-related regulatory actions by Japan's pharmaceutical regulatory agency.
    Ishiguro C; Misu T; Iwasa E; Izawa T
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1314-1320. PubMed ID: 28722235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review.
    Dias P; Penedones A; Alves C; Ribeiro CF; Marques FB
    Curr Drug Saf; 2015; 10(3):234-50. PubMed ID: 26219291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works.
    Santoro A; Genov G; Spooner A; Raine J; Arlett P
    Drug Saf; 2017 Oct; 40(10):855-869. PubMed ID: 28735357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intensive safety monitoring program of antineoplastic medicines: A pilot study in a Portuguese oncology hospital.
    Mendes D; Rigueiro G; Silva RS; Penedones A; Alves C; Sousa G; Batel-Marques F
    J Oncol Pharm Pract; 2020 Jan; 26(1):133-140. PubMed ID: 31117914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of medicines-Pharmacists' knowledge, practice, and attitudes toward pharmacovigilance and adverse drug reactions reporting process.
    Kopciuch D; Zaprutko T; Paczkowska A; Ratajczak P; Zielińska-Tomczak Ł; Kus K; Nowakowska E
    Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1543-1551. PubMed ID: 31148344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The new pharmacovigilance legislation in practice].
    Broekmans AW; Mol PG
    Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrating Regulatory Drug Label Information to Facilitate Evaluation of Adverse Events in Pharmacovigilance.
    Hui TZ
    Curr Drug Saf; 2020; 15(2):124-130. PubMed ID: 32091345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The value of patient reporting to the pharmacovigilance system: a systematic review.
    Inácio P; Cavaco A; Airaksinen M
    Br J Clin Pharmacol; 2017 Feb; 83(2):227-246. PubMed ID: 27558545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How do patients contribute to signal detection? : A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme.
    Hazell L; Cornelius V; Hannaford P; Shakir S; Avery AJ;
    Drug Saf; 2013 Mar; 36(3):199-206. PubMed ID: 23444232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A description of signals during the first 18 months of the EMA pharmacovigilance risk assessment committee.
    Pacurariu AC; Coloma PM; van Haren A; Genov G; Sturkenboom MC; Straus SM
    Drug Saf; 2014 Dec; 37(12):1059-66. PubMed ID: 25398646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Finding Needles in the Haystack: Clinical Utility Score for Prioritisation (CUSP), an Automated Approach for Identifying Spontaneous Reports with the Highest Clinical Utility.
    Kara V; Powell G; Mahaux O; Jayachandra A; Nyako N; Golds C; Bate A
    Drug Saf; 2023 Sep; 46(9):847-855. PubMed ID: 37535258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolution and key elements of the Brazilian pharmacovigilance system: a scoping review beginning with the creation of the Brazilian Health Regulatory Agency.
    Mota DM; Vigo Á; Kuchenbecker RS
    Cad Saude Publica; 2018 Oct; 34(10):e00000218. PubMed ID: 30328994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.